The 40 Over 40 list highlights an inspiring lineup of women who are reinventing, disrupting and making an impact in their fields. In her role as chief scientific officer,
"This is a well-deserved honor and distinction, and I am delighted to have had the privilege of working closely with Jessica over the past several years. Her many successes are an inspiration to those around her," said
Winners were selected based on a rigorous application and judging process that evaluated three areas: impact, role model and, reinvention and momentum. To view the complete list of 2016 winners, click here: http://fortyover40.com/honorees/.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development suspended), and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.
Liz Bryan Spectrum Science Communications, Inc.O: 202-955-6222 email@example.com For investors: Jonathan Poole Genocea Biosciences, Inc.O: 617-876-8191 firstname.lastname@example.org
News Provided by Acquire Media